Big Board

Content Ideas
Result Content Idea Research
Result Content Idea Research
1 Personalized Treatment Is Paramount in Colorectal Cancer
2 Real-World Study Confirms Safety of Regorafenib After Sorafenib in Unresectable HCC
3 Comparative Effectiveness of Systemic Treatments for Advanced HCC
4 Medison Pharma Enters Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize QINLOCK® (Ripretinib) in a Multi-Regional Agreement
5 Regorafenib Showed Modest Activity in Ewing Sarcoma
6 Dr. Kim on Efficacy and Next Steps of Phase 1/1b Study With Regorafenib + Nivolumab in CRC
7 Bleeding risk doubled during concurrent VEGFR–TKI, anticoagulant therapy
8 Nivolumab Plus Regorafenib Regimen Active in Gastrointestinal Cancers
9 Osteosarcoma Market Dynamics Expected to Grow with a CAGR of 5.70% Owing to Robust Pipeline and an Increase in Incidence for the Study period 2017-30, estimates DelveInsight
10 Regorafenib/Nivolumab Shows Modest Activity in MMR Proficient Advanced Refractory CRC
11 Deciphera Presents Data from QINLOCK® (Ripretinib) Program at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting
12 Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study
13 Cabozantinib May Be a Match for Regorafenib in Second line Advanced HCC
14 Novel Combination Active in Refractory GIST
15 Exploring Current Treatment Options for Patients With HCC
16 ASCO Systemic Therapy Guideline Developed for Advanced HCC
17 Regorafenib Plus TAS-102 Demonstrates Clinically Meaningful Disease Control in mCRC
18 A Phase II/III Study of Regorafenib versus Standard Therapy for Patients with Newly Diagnosed or Recurrent Glioblastoma (GBM AGILE)
19 Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial
20 Exploring Regorafenib and Nivolumab as Treatment for Colorectal Cancer
21 Dr. Cusnir on the Utility of Regorafenib in Gastric Cancer
22 Regorafenib for Metastatic Colorectal Cancer: Common Toxicities and Prevention Strategies
23 Multikinase inhibitor targets advanced biliary tract tumors
24 Dr. Grothey on Choosing Between Regorafenib and TAS-102 in mCRC
25 Bayer's Stivarga® (regorafenib) becomes first compound used in clinical trial platform to investigate new therapies for brain cancer
26 CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib
27 Stivarga, Opdivo have similar survival outcomes in HCC
28 Regorafenib/TAS-102 Induces Clinically Meaningful DCR in Refractory Metastatic CRC
29 Dose-Optimization Strategies Continue for Regorafenib in Colorectal Cancer With ReDOS Success
30 Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study
31 Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement to investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as combination therapy in patients with metastatic colorectal cancer
32 New drug for metastatic colorectal cancer enters phase 3 trial
33 Individualized Treatment Is Key for mCRC
34 Regorafenib/Nivolumab Combo to Be Studied in Phase III Trial of Patients With MSS mCRC
35 Regorafenib becomes First Drug used in Clinical Trial Platform to Investigate New Brain Cancer Therapies
36 Disease Control Achieved With Regorafenib in Refractory GIST Using Reduced, Continuous Dosing
37 Regorafenib Brings Positive Response Following Liver Transplantation
38 RESORCE Trial Analysis Shows Higher AFP Responses Achieved With Regorafenib in HCC
39 Atezolizumab/Bevacizumab Lays the Groundwork for Optimal Sequencing in HCC
40 PFS Doubled With Regorafenib in Locally Advanced Biliary Tract Cancer
41 Regorafenib dosing strategies reduce adverse events among patients with colorectal cancer
42 Colorectal Cancer Treatment Continues to Be Personalized
43 Nintedanib Market Size, Share, Application Analysis, Regional Outlook, Growth Tr
44 Bayer's regorafenib kicks off brain cancer platform trial
45 Liver Cancer Rates Are Rising; So Is Optimism Around Its Treatment
46 Bayer to showcase new data including research in immuno-oncology at ASCO GI Cancers Symposium 2020
47 Data demonstrate efficacy of more flexible dose of regorafenib to relieve side-effects in mCRC patients
48 Real-Life Analysis Confirms Benefit of Sorafenib/Regorafenib Sequence in HCC
49 Prognostic and predictive biomarkers in metastatic colorectal cancer patients receiving regorafenib
50 Regorafenib after sorafenib lengthens OS for advanced liver cancer
51 Regorafenib Dose Escalation Superior in Metastatic CRC
52 Regorafenib confers 'substantial' survival benefit in recurrent glioblastoma
53 Regorafenib not cost-effective as second-line therapy for hepatocellular carcinoma
54 First Patient Dosed in Trial of CS1001 Plus Stivarga for Advanced Tumors
55 Culprit in Regorafenib Combo Failure in Metastatic Colorectal Cancer?
56 Expert Discusses Real-World Data for Regorafenib in mCRC
57 A higher ctDNA fraction decreases survival in regorafenib‐treated metastatic colorectal cancer patients: Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study
58 Regorafenib to be tested in brain cancer patients in multi-arm cooperation trial | Small Molecules | News Channels
59 Regorafenib Sustains OS Benefit in RESORCE Trial Update
60 Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
61 Bayer's Regorafenib is the First Drug to Enter GBM AGILE
62 Regorafenib Extends Overall Survival in Patients With Recurring Glioblastoma
63 Regorafenib Safety, Efficacy in mCRC Confirmed in Published Results
64 Bayer's dominance in liver cancer challenged
65 Regorafenib/Nivolumab Combo to Be Explored in Phase III MSS CRC Trial
66 Dr. Lenz on Later-Line Combo Approaches in CRC
67 Regorafenib OS Benefit Sustained in Updated HCC Findings
68 Regorafenib Active in Patients With Aggressive Metastatic Osteosarcoma
69 The use of regorafenib for patients with refractory metastatic colorec | OTT
70 Regorafenib Plus Nivolumab Limits Tumor Growth In Gastric and Colorectal Cancers
71 NCCN Recommends Regorafenib Dose Escalation in Metastatic CRC
72 The Expanding Continuum of Care in Metastatic Colorectal Cancer
73 Bayer to Present Data from Growing Oncology Portfolio at the ASCO20 Virtual Scientific Program
74 Global Naldemedine Market Outlook 2025: Top Companies, Trends, Growth Factors Details by Regions, Types and Applications
75 Is Salvage Regorafenib or Enhanced Immunotherapy Optimal for Refractory Colon Cancer?
76 Bayer to Showcase New Data from Evolving Oncology Portfolio at ESMO Virtual Congress 2020
77 Boosting treatments for metastatic melanoma: Study shows repurposing a class of medications could give cancer therapies a better chance at fighting the disease
78 New Drug for Gastrointestinal Stromal Tumours (GIST) to be Launched in Australia, New Zealand and South East Asia Following Distribution Agreement
79 Regorafenib/Nivolumab Combo Elicits Responses in CRC and Gastric Cancer
80 Real-Life Experiences Demonstrate Benefit of Sorafenib-Regorafenib Sequential Therapy in Advanced HCC
81 Regorafenib Extends PFS in Locally Advanced Biliary Tract Cancer
82 Multikinase Inhibitor Extends PFS in Osteosarcoma
83 BRIEF-Ipsen Announces Publication Of First Matching-Adjusted Indirect Comparison Of Cabometyx (Cabozantinib) Versus Regorafenib
84 Bayer nets speedy US review for regorafenib in liver cancer
85 Novel Strategies Progress Through mCRC Pipeline
86 Bayer's Stivarga® (regorafenib) Tablets Approved by US FDA for Treatment of Patients with Locally Advanced, Unresectable or Metastatic GIST
87 Side Effects With Regorafenib Occur Early and Tend to Taper
88 Success of Regorafenib Confirmed in Patients With mCRC
89 David Kerr on ESMO's Most Important Colorectal Cancer Trials
90 UPDATED: Bayer, Onyx nab speedy FDA OK for regorafenib, prices at $9350
91 CONSIGN, CONCUR Confirm Efficacy of Regorafenib in mCRC
92 A Concise Review of the Changing Landscape of Hepatocellular Carcinoma
93 Ipsen Announces Publication of First Matching-Adjusted Indirect Comparison of Cabometyx® (cabozantinib) Versus regorafenib in Advanced Hepatocellular Carcinoma in Advances in Therapy
94 Life extending treatment for patients with advanced liver cancer recommended by NICE
95 Bayer to Present New Data from Evolving Oncology Portfolio at ESMO 2020
96 Stivarga and Opdivo Provide Comparable Survival Benefits for People With Liver Cancer
97 Regorafenib Ups Progression-Free Survival in Several Soft-Tissue Sarcomas
98 Bekaii-Saab Reflects on Recent Regorafenib Data in mCRC
99 Dr. Eng on Roles of Regorafenib and TAS-102 in CRC Treatment
100 Regorafenib shows significant survival gains in refractory liver cancer: Phase III trial confirms efficacy and safety of new second-line agent